March 8, 2021 -- Baxter BioPharma has entered into an agreement with Moderna to provide fill/finish sterile manufacturing services and supply packaging for approximately 60-90 million doses of the Moderna COVID-19 vaccine in 2021.
Baxter is a contract manufacturing organization that specializes in parenteral (injected) pharmaceuticals, including vaccines. The manufacturing of Moderna's messenger RNA (mRNA)-based vaccine will take place at Baxter's fill/finish sterile manufacturing facilities located in Bloomington, IN. The site has capabilities and expertise in injectable delivery systems and clinical and commercial vaccine manufacturing.
Financial details of the agreement were not disclosed.
Copyright © 2021 scienceboard.net